靶向CXCR4治疗急性白血病的过去、现在和未来--急性白血病治疗的新希望  

The past,present,and future of targeting CXCR4 in acute leukemia treatment-new hope for acute leukemia

作　　者：苏龙[1] Su Long(Department of Hematology,the First Hospital of Jilin University,Changchun 130021,Jilin China)

机构地区：[1]吉林大学第一医院血液科,吉林长春130021

出　　处：《中国医学前沿杂志（电子版）》2022年第9期1-4,I0004,共5页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：急性白血病是严重威胁人类健康的恶性血液系统疾病,复发是其治疗失败的关键所在。骨髓微环境的保护作用在白血病复发中发挥重要作用,而白血病细胞向骨髓归巢与定植受趋化因子受体(c-x-c motif chemokine receptor 4,CXCR4)的调控。阻断CXCR4动员白血病细胞脱离其保护性骨髓微环境可有效促进白血病细胞被化疗药物或分子靶向治疗药物杀伤。阻断CXCR4联合化疗或分子靶向治疗药物是急性白血病潜在的治疗方案,但临床试验结果显示其疗效改善有限。因此,新的联合治疗策略仍有待更多研究探索,以进一步提高该治疗策略的疗效,改善急性白血病患者的整体治疗效果。Acute leukemia is a malignant hematological disease that seriously threatens human health,and relapse after treatment remains the major obstacle for the success of treatment.Bone marrow microenvironment plays a critical role in the relapse of acute leukemia,while the homing and retention of leukemia cells in bone marrow is regulated by c-x-c motif chemokine receptor 4(CXCR4)pathway.Leukemia cells could be mobilized from their protective bone marrow microenvironment into periphery by CXCR4 blockade.CXCR4 blockade could significantly increase the cytotoxicity of chemotherapeutic and molecular target drugs.However,the efficacy was limited when clinical trials were performed.Thus,new treatment strategies combined with CXCR4 antagonists are still needed to be explored to improve the efficacy and achieve more favorable outcomes for patients with acute leukemia.

关 键 词：急性白血病 治疗 趋化因子受体 

分 类 号：R733.71[医药卫生—肿瘤]